News &
Media
-
Neurotech International Phase I/II Autism Results Due this Quarter
View MoreIn July last year Neurotech International (NTI: $0.05) acquired a license from Dolce CannGroup for access to specific proprietary strains of cannabis for the potential treatment of various neurological conditions.
-
Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans
View More -
From Backstreet to Highstreet: How Cannabis Has Entered the Mainstream
View MoreExplore the $31.96 billion global cannabis market that is disrupting the healthcare and pharmaceutical industries.
-
Australia’s Neurotech Inks Cannabis Cultivation Partnership
View MoreNeurotech International Limited (ASX:NTI) has established a strategic medical cannabis cultivation partnership with CannaPacific Limited.
-
Neurotech just started world’s first THC-less cannabis study in autistic children
View MoreThe Phase I/II clinical trial announced today is a groundbreaking study where medicinal cannabis containing little to no THC is being tested on autistic children.
-
Neurotech embarks on ground-breaking ASD trials
View MoreNeurotech International Limited (ASX:NTI) has commenced a Phase I/II open label clinical study in 20 children aged between 5-17 years with Autism Spectrum Disorder (ASD).
-
Neurotech International (ASX:NTI) secures option to Dolce Cann Global’s cannabis strains
View MoreNeurotech International (NTI) has secured an option to acquire an exclusive worldwide licence to use cannabis strains from Dolce Cann Global.
The proprietary cannabis strains will be medicinally used to treat neurological disorders such as autism, epilepsy and ADHD.